Hyperlipidemia and thrombotic complications in patients with membranous nephropathy

Seminars in Nephrology

Volumn 23, Issue 4, 2003, Pages 406-411

  Nickolas, Thomas L ^b   Radhakrishnan, Jai ^b   Appel, Gerald B ^a  

^a Presbyterian Hospital ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ANTICOAGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; DEEP VEIN THROMBOSIS; DISEASE COURSE; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; LUNG EMBOLISM; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS;

EID: 0041887361     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9295(03)00058-5     Document Type: Article

References (53)

1. Watts GF, Herrmann S, Dogra GK, et al: Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 60:182-189, 2001
2. Dogra GK, Watts GF, Herrmann S, et al: Statin therapy improves brachial artery dysfunction in nephrotic syndrome. Kidney Int 62:550-557, 2002
3. Mantarri M, Tiula E, Alikosi T, et al: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26:670-676, 1995
4. Kamanna VS, Roh DD, Kirschenbaum MA: Atherogenic lipoproteins: Mediators of glomerular injury. Am J Nephrol 13:1-5, 1993
5. Samuelsson O, Mulec H, Knight-Gibson PO, et al: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
6. Muntner P, Coresh J, Smith JC, et al: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int 58:293-301, 2000
7. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
8. van Dijk MA, Kamper AM, van Veen S, et al: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16:2152-2157, 2001
9. Appel GB, Blum CB, Chien S, et al: The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312: 1544-1548, 1985
10. Radhakrishnan J, Appel AS, Valeri A, et al: The nephritic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22:135-142, 1993
11. Ordonez JD, Hiatt RA, Killebrew EJ, et al: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
12. Al-Shebeb T, Frohlich J, Magil AB: Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. Kidney Int 33:498-507, 1988
13. Kasiske BL, O'Donnell MP, Cleary MP, et al: treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988
14. Kasiske BL, O'Donnell MP, Garvis WJ, et al: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62:367-374, 1988
15. Kasiske BL, O'Donnell MP, Schmitz PG, et al: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 37:880-891, 1990
16. De Sain-vander Velden MG, Kaysen GA, Barrett HA, et al: Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53:994-1001, 1998
17. Murdoch SJ, Breckenridge WC: Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 118:193-212, 1995
18. Saski A, Goldberg IJ: Lipoprotein lipase release from BFC-1 beta adipocytes. Effects of triglyceride-rich lipoproteins and lipolysis products. J Biol Chem 267:15198-15204, 1992
19. Kaysen GA, Pan XM, Couser WG, et al: Defective lipolysis persists in hearts of rats with Heymann nephritis in the absence of nephrotic plasma. Am J Kidney Dis 22:128-134, 1993
20. Liang K, Vaziri ND: Down regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 51:1933-1937, 1997
21. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 25:1017-1058, 1984
22. Sich D, Saidi Y, Giral P, et al: Characterization of two HDL subfractions and LpA-I, LpA-I: LpA-II distribution profiles and clinical characteristics of hyperalphalipoproteinemic subjects without cholesterol ester transfer protein deficiency. Atherosclerosis 138:251-260, 1998
23. Moulin P, Appel GB, Ginsberg HN, et al: Increased concentration of plasma CETP in the nephritic syndrome: Role in dyslipidemia. J Lipid Res 33:1817-1822, 1992
24. Appel G: Lipid abnormalities in renal disease. Kidney Int 39:169-183, 1991
25. Gavish D, Azrolan N, Breslow J: Plasma Lp(a) concentration is inversely correlated with the ratio of kringle IV/kringle V encoding domains in the apo(a) gene. J Clin Invest 84:2021-2027, 1989
26. Warmer C, Rader D, Bardens W, et al: Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
27. De Sain-van der Velden MGM, Jan Reijngoud D, Kaysen GA, et al: Evidence for increased synthesis of lipoprotein (a) in the nephrotic syndrome. J Am Soc Nephrol 9:1474-1481, 1998
28. Massy ZA, Ma JZ, Louis TA, et al: Lipid-lowering therapy in patients with renal disease. Kidney Int 48:188-198, 1995
29. Thomas ME, Harris KPG, Ramaswamy C, et al: Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44:1124-1129, 1993
30. Spitalewitz S, Porush JG, Cattran D, et al: Treatment of hyperlipidemia in the nephrotic syndrome: The effects of pravastatin therapy. Am J Kidney Dis 22:143-150, 1993
31. Valeri A, Gelfand J, Blum C, et al: Treatment of hyperlipidemia of the nephrotic syndrome: A controlled trial. Am J Kidney Dis 8:388-396, 1986
32. Knopp RH: Ezetimibe. N Engl J Med 341:498-511, 1995
33. Gagne C, Bays HE, Weiss SR, et al: Efficacy and safety of eletimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90: 1084-1091, 2002
34. Cameron JS: Complications of the nephrotic syndrome, Cameroon JS, Glassock RJ, (eds): The Nephrotic Syndrome. New York, Marcel Dekker, 1988, pp 849-870
35. Llach F: Hypercoagulability, renal vein thrombosis, and other complications of the nephrotic syndrome. Kidney Int 28:429-439, 1985
36. Velasquez FF, Prugue NG, Morales NR: Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 8:457-562, 1988
37. Dalen JE, Paraskos JA, Ocksene IS, et al: Venous thromboembolism, scope of the problem. Chest 24:S370-S374, 1986 (suppl II)
38. Wagoner RD, Stanson AW, Holley KE, et al: Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: Incidence and significance. Kidney Int 23: 368-374, 1983
39. Llach F, Papper S, Massry SG: The clinical spectrum of renal vein thrombosis: Acute and chronic. Am J Med 69:819-827, 1980
40. Benett WM: Renal vein thrombosis in nephrotic syndrome. Klin Wochenschr 58:399-407, 1980
41. Ardiles L, Mezzano S, Arriagada A, et al: Clinical course in 51 patients with idiopathic membranous glomerulopathy. Rev Med Chil 117:266-272, 1989
42. Kafner A: Coagulation factors in nephrotic syndrome. Am J Nephrol 10:S63-S68, 1990 (suppl)
43. Kaufman RH, Veltramp JJ, Tilburg NH, et al: Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 65:607-613, 1978
44. Moser KM, Lemoine JR: Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 94:439-443, 1981
45. Bell WR, Simon TL: Current status of pulmonary thromboembolic disease: Pathophysiology, diagnosis, prevention, and treatment. Am Heart J 103:239-262, 1982
46. Carson JL, Kelley MA, Duff A, et al: The clinical course of pulmonary embolism. N Engl J Med 326:1240-1245, 1992
47. Noel LH, Zanetti M, Droz D, et al: Long-term prognosis of idiopathic membranous glomerulonephritis: Study of 116 untreated patients. Am J Med 66:82-90, 1979
48. Levine MN, Raskob G, Hirsch J: Hemorrhagic complications of long-term anticoagulation therapy. Chest 95:S26-S36, 1989 (suppl)
49. Landefeld CS, Cook EF, Flatley M, et al: Identification and preliminary validation of major bleeding in hospitalized patients starting anticoagulation therapy. Am J Med 82:703-713, 1987
50. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144-152, 1989
51. Sarasin FP, Schifferli JA: Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45:578-585, 1994
52. Orth SR, Ritz E: The nephrotic syndrome. N Engl J Med 338:1202-1211, 1998
53. Isom R, Appel GB: Treatment of the nephrotic syndrome, in Fauci A, Lichtenstein LM (eds): Therapy of Allergic and Immunologic Disease. St Louis, Mosby, 2003